Your browser doesn't support javascript.
The SARS-CoV-2 spike residues 616/644 and 1138/1169 delineate two antibody epitopes in COVID-19 mRNA COMINARTY vaccine (Pfizer/BioNTech).
Andries, Jessica; Viranaicken, Wildriss; Cordonin, Colette; Herrscher, Charline; Planesse, Cynthia; Roquebert, Bénédicte; Lagrange-Xelot, Marie; El-Kalamouni, Chaker; Meilhac, Olivier; Mavingui, Patrick; Couret, David; Gadea, Gilles; Despres, Philippe.
  • Andries J; Université de La Réunion, INSERM U1187, CNRS UMR 9192, IRD UMR 249, Unité Mixte Processus Infectieux en Milieu Insulaire Tropical (PIMIT), Plateforme Technologique CYROI, 94791 Sainte Clotilde, La Réunion, France.
  • Viranaicken W; Université de La Réunion, INSERM U1187, CNRS UMR 9192, IRD UMR 249, Unité Mixte Processus Infectieux en Milieu Insulaire Tropical (PIMIT), Plateforme Technologique CYROI, 94791 Sainte Clotilde, La Réunion, France.
  • Cordonin C; Plate-Forme Technologique CYROI, 94791 Sainte Clotilde, La Réunion, France.
  • Herrscher C; Université de La Réunion, INSERM U1187, CNRS UMR 9192, IRD UMR 249, Unité Mixte Processus Infectieux en Milieu Insulaire Tropical (PIMIT), Plateforme Technologique CYROI, 94791 Sainte Clotilde, La Réunion, France.
  • Planesse C; Université de La Réunion, INSERM U1188, Unité Mixte Diabète Athérothrombose Thérapies Réunion Océan Indien (DeTROI), Plateforme Technologique CYROI, 94791 Sainte Clotilde, La Réunion, France.
  • Roquebert B; Laboratoire CERBA, Parc d'activités « Les Béthunes ¼, 95310, Saint-Ouen-l'Aumône, France.
  • Lagrange-Xelot M; Centre Hospitalier Felix Guyon, Centre Hospitalier Universitaire-La Réunion, 97000, Saint-Denis, La Réunion, France.
  • El-Kalamouni C; Université de La Réunion, INSERM U1187, CNRS UMR 9192, IRD UMR 249, Unité Mixte Processus Infectieux en Milieu Insulaire Tropical (PIMIT), Plateforme Technologique CYROI, 94791 Sainte Clotilde, La Réunion, France.
  • Meilhac O; Université de La Réunion, INSERM U1188, Unité Mixte Diabète Athérothrombose Thérapies Réunion Océan Indien (DeTROI), Plateforme Technologique CYROI, 94791 Sainte Clotilde, La Réunion, France.
  • Mavingui P; Université de La Réunion, INSERM U1187, CNRS UMR 9192, IRD UMR 249, Unité Mixte Processus Infectieux en Milieu Insulaire Tropical (PIMIT), Plateforme Technologique CYROI, 94791 Sainte Clotilde, La Réunion, France.
  • Couret D; Université de La Réunion, INSERM U1188, Unité Mixte Diabète Athérothrombose Thérapies Réunion Océan Indien (DeTROI), Plateforme Technologique CYROI, 94791 Sainte Clotilde, La Réunion, France.
  • Gadea G; Groupe Hospitalier Sud Réunion, Centre Hospitalier Universitaire-La Réunion, 97410, Saint-Pierre, La Réunion, France.
  • Despres P; Université de La Réunion, INSERM U1187, CNRS UMR 9192, IRD UMR 249, Unité Mixte Processus Infectieux en Milieu Insulaire Tropical (PIMIT), Plateforme Technologique CYROI, 94791 Sainte Clotilde, La Réunion, France.
Sci Rep ; 12(1): 5999, 2022 04 09.
Article in English | MEDLINE | ID: covidwho-1921692
ABSTRACT
The newly identified coronavirus SARS-CoV-2 is responsible for the worldwide pandemic COVID-19. Considerable efforts have been devoted for the development of effective vaccine strategies against COVID-19. The SARS-CoV-2 spike protein has been identified as the major antigen candidate for the development of COVID-19 vaccines. The Pfizer-BioNTech COVID-19 vaccine COMIRNATY is a lipid nanoparticle-encapsulated mRNA encoding a full-length and prefusion-stabilized SARS-CoV-2 spike protein. In the present study, synthetic peptide-based ELISA assays were performed to identify linear B-cell epitopes into the spike protein that contribute to elicitation of antibody response in COMIRNATY-vaccinated individuals. The synthetic S2P6 peptide containing the spike residues 1138/1169 and to a lesser extent, the synthetic S1P4 peptide containing the spike residues 616/644 were recognized by the immune sera from COMIRNATY vaccine recipients but not COVID-19 recovered patients. We assume that the synthetic S2P6 peptide and to a lesser extent the synthetic S1P4 peptide, could be of interest to measure the dynamic of antibody response to COVID-19 mRNA vaccines. The S2P6 peptide has been identified as immunogenic in adult BALB/c mice that received protein-peptide conjugates in a prime-boost schedule. This raises the question on the role of the B-cell epitope peptide containing the SARS-CoV-2 spike residues 1138/1169 in protective efficacy of the Pfizer-BioNTech COVID-19 vaccine COMIRNATY.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: Epitopes, B-Lymphocyte / Spike Glycoprotein, Coronavirus / COVID-19 Vaccines / COVID-19 / Antibodies, Viral Topics: Vaccines Limits: Animals / Humans Language: English Journal: Sci Rep Year: 2022 Document Type: Article Affiliation country: S41598-022-10057-7

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Epitopes, B-Lymphocyte / Spike Glycoprotein, Coronavirus / COVID-19 Vaccines / COVID-19 / Antibodies, Viral Topics: Vaccines Limits: Animals / Humans Language: English Journal: Sci Rep Year: 2022 Document Type: Article Affiliation country: S41598-022-10057-7